Nearly all the patients with severe SCD treated with the gene-editing therapy reni-cel remained free of VOEs for up to two ...

The majority of SCD patients given Lyfgenia in clinical trials remained free of vaso-occlusive events (VOEs) following ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

VOEs and severe vaso-occlusive events (sVOEs) were eliminated or significantly reduced in all patients. Specific findings include: 36/38 (94.7%) of evaluable patients achieved complete resolution ...

VOEs and severe vaso-occlusive events were eliminated or significantly reduced in all patients. Specific findings include: 36/38 of evaluable patients achieved complete resolution of severe VOEs ...